三阴性乳腺癌HER2(0/1+)和HER2(2+)的相关基因表达差异

Gene expression difference between HER2(0/1+) and HER2(2+) in the triple-negative breast cancers

目的：探讨三阴性乳腺癌（TNBC）HER2（0/1＋）和HER2（2＋）两组中CK5/6、EGFR、VEGF、COX-2和TOPⅡα的表达差异及其临床意义。方法：收集2010年1月~2014年12月TNBC患者HER2（0/1＋）组30例,HER2（2＋）组15例,采用免疫组织化学方法检测CK5/6、EGFR、VEGF、COX-2和TOPⅡα的表达。结果：与HER2（2＋）组比较,HER2（0/1＋）组中CK5/6、EGFR、VEGF、COX-2和TOPⅡα的表达均偏高,但不具有统计学差异（P〉0.05）;且与患者年龄、肿瘤大小、病理学类型及分级、淋巴结转移、脉管侵犯均无相关性（P〉0.05）。结论：TNBC HER2（0/1＋）和HER2（2＋）两者存在一些基因表达差异,可能为临床靶向治疗药物的选择提供理论依据。

Objective： To investigate the expression difference of CK5 /6,EGFR,VEGF,COX-2,TOPⅡα genes and their clinical significance between HER2（ 0 /1 ＋） and HER2（ 2 ＋） in the triple-negative breast cancers（ TNBC）. Methods： Thirty cases of TNBC with HER2（ 0 /1 ＋） and 15 with HER2（ 2 ＋） were included. Immunohistochemistry was performed to detect the expression of CK5 /6,EGFR,VEGF,COX-2 and TOPⅡα in the tissue specimens obtained from the TNBC cases. Results： Up-regulated expression of CK5 /6,EGFR,VEGF,COX-2 and TOPⅡα was observed in cases of HER2（ 0 /1 ＋）,yet the difference was not statistically significant,and expression of these genes was not correlated with the patient＇s ages,tumor size,type of pathology,histology grade,lymph node metastasis and vascular invasion（ P〈0. 05）. Conclusion： Expression of HER2（ 0 /1 ＋） appears somewhat different from that of in TNBC,and this biological marker may be an important theoretical support to molecular target therapy for TNBC.